Welcome To Mylan Inc.

A Legacy You Can Count On

Mylan is the third-largest generic pharmaceutical company in the world. We hold top-five positions in 13 different established markets worldwide and are building a strong presence in many emerging generics markets.

Today, we market more than 570 products to consumers in more than 140 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. We also have the deepest pipeline and largest number of products pending regulatory approval in company history.

At Mylan, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues – from complex research, development and regulatory conditions to rapidly changing consumer demands.

Whether we’re improving the health of patients worldwide or meeting the diverse needs of our customers, Mylan delivers. Every time, all the time.

More About Mylan

If you have difficulty finding the information you are looking for, please contact us, and we will personally help you with your request.

06/29/2009 - Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market... (more)
06/17/2009 - Mylan Receives FDA Approval for Additional Strength of Generic Restoril®... (more)
06/03/2009 - Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period... (more)
06/01/2009 - Mylan's Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs... (more)
06/01/2009 - Mylan Announces Successful Matrix Delisting Offer... (more)
Legal & Copyright Disclaimer. © Copyright 2009 Mylan Inc. All rights reserved. Privacy Policy.